The United Kingdom and the United States have forged a significant commercial pact that will keep no tariffs on UK drug exports entering the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to increase funding on medicines through the NHS. This commitment guarantees that duties on these crucial products will be held at nothing for a period of the next three years.
This agreement is in response to recent warnings to dramatically increase duties on branded pharmaceutical products, with potential rates mentioned as high as 100%.
"This agreement between the Britain bolsters the international landscape for innovative medicines and brings much-needed fairness to U.S.–U.K. pharmaceutical trade," a release said.
Commercial Impact
Pharmaceuticals are one of the the United Kingdom's biggest goods shipped to the United States, which is clearly the biggest destination for major companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period to the end of last September, the UK sold medicines valued at billions to the US. This amount accounted for a significant portion of British export trade in that timeframe.
"This agreement protects work, increases capital expenditure and sets the stage for the UK to emerge as a worldwide center for life sciences," a minister commented.
Detailed NHS Changes
The deal involves several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new medicines to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to double total health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The amount manufacturers must refund to the NHS to stay within budget will be restricted at 15%. Previously, refunds were more than twenty percent.
Recent Tensions
The pact comes amid a long-running dispute between the sector and the ministers over drug pricing and NHS adoption.
The disagreement were intensified by assertions that US consumers were paying a premium for the same drugs than people in the UK and Europe.
In recent months, several significant manufacturing plans in the UK have been halted or cancelled, while substantial expansions have been announced toward American operations.
A senior figure acknowledged that the NHS must spend more on drugs, noting that its budget allocation on drugs had decreased as a share of its resources over the last ten years.
